Dual CRALBP isoforms unveiled: iPSC-derived retinal modelling and AAV2/5-RLBP1 gene transfer raise considerations for effective therapy

Author:

Damodar Krishna,Dubois Gregor,Guillou Laurent,Mamaeva DariaORCID,Pequignot MarieORCID,Erkilic Nejla,Sanjurjo-Soriano CarlaORCID,Boukhaddaoui HassanORCID,Bernex FlorenceORCID,Bocquet BéatriceORCID,Vialaret Jerome,Arsenijevic YvanORCID,Redmond T. MichaelORCID,Hirtz ChristopherORCID,Meunier IsabelleORCID,Brabet PhilippeORCID,Kalatzis VasilikiORCID

Abstract

AbstractInherited retinal diseases (IRDs) are clinically and genetically heterogeneous disorders characterised by progressive vision loss. Over 270 causative genes have been identified and variants within the same gene can give rise to clinically distinct disorders. Human induced pluripotent stem cells (iPSCs) have revolutionised disease modelling, by allowing pathophysiological and therapeutic studies in the patient and tissue context. The IRD geneRLBP1encodes CRALBP, an actor of the rod and cone visual cycles in the retinal pigment epithelium (RPE) and Müller cells, respectively. Variants inRLBP1lead to three clinical subtypes: Bothnia dystrophy, Retinitis punctata albescens and Newfoundland rod-cone dystrophy. We modelledRLBP1-IRD subtypes by patient-specific iPSC-derived RPE and identified pertinent therapeutic read-outs. We developed an AAV2/5-mediated gene replacement strategy and provided a proof-of-concept in theex vivohuman models that was validated in anin vivo Rlbp1−/−murine model. Most importantly, we identified a previously unsuspected smaller CRALBP isoform that is naturally and differentially expressed in both human and murine retina. The new isoform arises from an alternative methionine initiation site and plays a role in the visual cycle. This work provides novel insights into CRALBP expression andRLBP1-associated pathophysiology and raises important considerations for successful gene supplementation therapy.

Publisher

Cold Spring Harbor Laboratory

Reference63 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3